Biocon founder and chairperson Kiran Mazumdar-Shaw has formally laid out a succession plan, identifying her niece Claire Mazumdar as the future leader of the company, according to an interview with Fortune India.
Mazumdar-Shaw, who built Biocon into one of India’s leading biotechnology firms over four decades, said the decision reflects her confidence in Claire’s ability to lead the company’s next phase, particularly as it pivots towards advanced biotech and artificial intelligence.
“I am the sole owner of Biocon, and I need to make sure that I put it in good hands,” she said, adding that Claire has already demonstrated the capability to run a company.
The transition, however, will not be immediate. Mazumdar-Shaw indicated that she plans to remain actively involved, noting in a post on X that she is “not planning to hang up my boots for a while” and that Claire will move into the role in a phased manner.
Claire Mazumdar currently heads Bicara Therapeutics, a Nasdaq-listed firm incubated by Biocon. She holds degrees from Massachusetts Institute of Technology and Stanford University, including a doctorate in cancer biology, and has previously worked with Third Rock Ventures and Rheos Medicines. Bicara went public in 2024 and has since grown into a billion-dollar enterprise.
Mazumdar-Shaw also pointed to a wider support system within the family, including Claire’s brother Eric Mazumdar, an artificial intelligence expert at California Institute of Technology, and her husband Thomas Roberts of Massachusetts General Hospital.
The succession plan comes alongside broader restructuring within the Biocon group. The company has merged its generics and biologics businesses, streamlined operations, and reduced debt, while sharpening its focus on biosimilars, a segment that contributes around 60 per cent of its revenue. Biocon currently has 12 biosimilar products in the market and nearly 20 in development.
Leadership changes are also underway across its subsidiaries. Shreehas Tambe has taken over as CEO and managing director of Biocon Biologics, while Siddharth Mittal is set to lead Syngene International from July 1.
Mazumdar-Shaw said Biocon’s future growth strategy will centre on differentiated biosimilars, development of original biologic drugs, and deeper integration of artificial intelligence across research and development.
Shares of Biocon were trading 1.23 per cent higher at Rs 365.05 on Tuesday morning.
